肿瘤突变负荷-话题@MedSci

#肿瘤突变负荷#

10篇内容 | 1663人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2259891, encodeId=8d3022598910b, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=0de5290588c' target=_blank style='color:#2F92EE;'>#免疫检查点抑制剂#</a> <a href='/topic/show?id=b1848304800' target=_blank style='color:#2F92EE;'>#肿瘤突变负荷#</a>, objectTitle=PNAS：癌症免疫疗法的新突破！DDX54或有望成为关键靶点, objectType=article, longId=871259, objectId=baec8e1259e2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20250409/1744199532145_1938376.png, objectUrl=/article/show_article.do?id=baec8e1259e2, replyNumber=0, likeNumber=12, createdTime=2025-04-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2211258, encodeId=100422112584e, content=<a href='/topic/show?id=daf52906537' target=_blank style='color:#2F92EE;'>#免疫治疗#</a> <a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a> <a href='/topic/show?id=b1848304800' target=_blank style='color:#2F92EE;'>#肿瘤突变负荷#</a>, objectTitle=高价基因有必要吗？最新报道肿瘤突变负荷TMB与PD-1的疗效无显著相关性！, objectType=article, longId=831313, objectId=ffa18313134a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240622/1719050865437_5579292.jpg, objectUrl=/article/show_article.do?id=ffa18313134a, replyNumber=0, likeNumber=131, createdTime=2024-06-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ffa18313134a, moduleTitle=高价基因有必要吗？最新报道肿瘤突变负荷TMB与PD-1的疗效无显著相关性！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffa18313134a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1486843, encodeId=a17f1486843e3, content=<a href='/topic/show?id=b1848304800' target=_blank style='color:#2F92EE;'>#肿瘤突变负荷#</a>, objectTitle=Nature Cancer观点 | 肿瘤突变负荷与免疫治疗的现状, objectType=article, longId=734642, objectId=cff3e34642ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cff3e34642ed, replyNumber=0, likeNumber=95, createdTime=2022-08-06, rootId=0, userName=howi, userId=df458217553, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cff3e34642ed, moduleTitle=Nature Cancer观点 | 肿瘤突变负荷与免疫治疗的现状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cff3e34642ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1486842, encodeId=879c1486842df, content=<a href='/topic/show?id=b1848304800' target=_blank style='color:#2F92EE;'>#肿瘤突变负荷#</a>, objectTitle=Nature Cancer观点：肿瘤突变负荷与免疫治疗的现状, objectType=article, longId=733992, objectId=5264e3399282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5264e3399282, replyNumber=0, likeNumber=96, createdTime=2022-08-01, rootId=0, userName=howi, userId=df458217553, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5264e3399282, moduleTitle=Nature Cancer观点：肿瘤突变负荷与免疫治疗的现状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5264e3399282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1486841, encodeId=a1b9148684149, content=<a href='/topic/show?id=b1848304800' target=_blank style='color:#2F92EE;'>#肿瘤突变负荷#</a>, objectTitle=AACR重磅：高基因扩增和肿瘤突变负荷组合作为接受替雷丽珠单抗治疗患者的泛癌生物标志物, objectType=article, longId=723965, objectId=ef58e23965b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef58e23965b0, replyNumber=0, likeNumber=95, createdTime=2022-04-12, rootId=0, userName=howi, userId=df458217553, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef58e23965b0, moduleTitle=AACR重磅：高基因扩增和肿瘤突变负荷组合作为接受替雷丽珠单抗治疗患者的泛癌生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef58e23965b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1486840, encodeId=102e1486840e2, content=<a href='/topic/show?id=b1848304800' target=_blank style='color:#2F92EE;'>#肿瘤突变负荷#</a>, objectTitle=AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）+化疗（chemo）与单独化疗在晚期非鳞状非小细胞肺癌（nsq-NSCLC）一线治疗的临床结局研究, objectType=article, longId=723964, objectId=100be239645b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=100be239645b, replyNumber=0, likeNumber=100, createdTime=2022-04-12, rootId=0, userName=howi, userId=df458217553, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=100be239645b, moduleTitle=AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）+化疗（chemo）与单独化疗在晚期非鳞状非小细胞肺癌（nsq-NSCLC）一线治疗的临床结局研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=100be239645b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1486839, encodeId=a0d41486839c1, content=<a href='/topic/show?id=b1848304800' target=_blank style='color:#2F92EE;'>#肿瘤突变负荷#</a>, objectTitle=ESMO Open：肿瘤突变负荷可预测口腔鳞状细胞癌患者预后, objectType=article, longId=212770, objectId=6d66212e701d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d66212e701d, replyNumber=0, likeNumber=105, createdTime=2021-06-17, rootId=0, userName=howi, userId=df458217553, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d66212e701d, moduleTitle=ESMO Open：肿瘤突变负荷可预测口腔鳞状细胞癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d66212e701d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1486838, encodeId=0ed2148683816, content=<a href='/topic/show?id=b1848304800' target=_blank style='color:#2F92EE;'>#肿瘤突变负荷#</a>, objectTitle=Cancer Immunol Immunother：肿瘤突变评分(TMS)取代肿瘤突变负荷(TMB)预测NSCLC患者对ICI治疗的反应性？, objectType=article, longId=206834, objectId=5369206834ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5369206834ca, replyNumber=0, likeNumber=100, createdTime=2021-02-07, rootId=0, userName=howi, userId=df458217553, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5369206834ca, moduleTitle=Cancer Immunol Immunother：肿瘤突变评分(TMS)取代肿瘤突变负荷(TMB)预测NSCLC患者对ICI治疗的反应性？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5369206834ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1486837, encodeId=ef2c148683ee4, content=<a href='/topic/show?id=b1848304800' target=_blank style='color:#2F92EE;'>#肿瘤突变负荷#</a>, objectTitle=Clin Cancer Res：根据ctDNA量化的肿瘤突变负荷可很好的预测转移性NSCLC患者是否能从免疫治疗中获益, objectType=article, longId=206791, objectId=9e27206e91ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e27206e91ca, replyNumber=0, likeNumber=77, createdTime=2021-02-06, rootId=0, userName=howi, userId=df458217553, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e27206e91ca, moduleTitle=Clin Cancer Res：根据ctDNA量化的肿瘤突变负荷可很好的预测转移性NSCLC患者是否能从免疫治疗中获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e27206e91ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1486836, encodeId=a1cb1486836d1, content=<a href='/topic/show?id=b1848304800' target=_blank style='color:#2F92EE;'>#肿瘤突变负荷#</a>, objectTitle=Lancet Oncol：肿瘤突变负荷联合IFNγ基因表达特征可预测靶向治疗的III期黑色素瘤患者的预后, objectType=article, longId=187354, objectId=313c18e3543f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=313c18e3543f, replyNumber=0, likeNumber=104, createdTime=2020-02-05, rootId=0, userName=howi, userId=df458217553, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=313c18e3543f, moduleTitle=Lancet Oncol：肿瘤突变负荷联合IFNγ基因表达特征可预测靶向治疗的III期黑色素瘤患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=313c18e3543f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1486835, encodeId=c1e21486835f6, content=<a href='/topic/show?id=b1848304800' target=_blank style='color:#2F92EE;'>#肿瘤突变负荷#</a>, objectTitle=[WCLC2017]胡洁教授深入解读ctDNA检测肿瘤突变负荷（TMB）在中国肺癌免疫治疗中的应用, objectType=article, longId=116642, objectId=d179116642cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d179116642cc, replyNumber=0, likeNumber=102, createdTime=2017-10-20, rootId=0, userName=howi, userId=df458217553, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d179116642cc, moduleTitle=[WCLC2017]胡洁教授深入解读ctDNA检测肿瘤突变负荷（TMB）在中国肺癌免疫治疗中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d179116642cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1486834, encodeId=5e41148683468, content=<a href='/topic/show?id=b1848304800' target=_blank style='color:#2F92EE;'>#肿瘤突变负荷#</a>, objectTitle=N Engl J Med：肿瘤突变负荷能为纳武单抗一线治疗晚期NSCLC争取一席之地吗, objectType=article, longId=103880, objectId=d0ce1038808e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0ce1038808e, replyNumber=0, likeNumber=89, createdTime=2017-06-30, rootId=0, userName=howi, userId=df458217553, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0ce1038808e, moduleTitle=N Engl J Med：肿瘤突变负荷能为纳武单抗一线治疗晚期NSCLC争取一席之地吗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0ce1038808e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

肿瘤突变负荷

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#肺癌# #免疫检查点抑制剂# #肿瘤突变负荷#

2025-04-10发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#免疫治疗# #PD-1抑制剂# #肿瘤突变负荷#

高价基因有必要吗？最新报道肿瘤突变负荷TMB与PD-1的疗效无显著相关性！

2024-06-23发表于上海

howi (审核中...)

前往app查看评论内容

#肿瘤突变负荷#

Nature Cancer观点 | 肿瘤突变负荷与免疫治疗的现状

2022-08-06

howi (审核中...)

前往app查看评论内容

#肿瘤突变负荷#

Nature Cancer观点：肿瘤突变负荷与免疫治疗的现状

2022-08-01

howi (审核中...)

前往app查看评论内容

#肿瘤突变负荷#

AACR重磅：高基因扩增和肿瘤突变负荷组合作为接受替雷丽珠单抗治疗患者的泛癌生物标志物

2022-04-12

howi (审核中...)

前往app查看评论内容

#肿瘤突变负荷#

AACR重磅之RATIONALE-304：肿瘤突变负荷（TMB）与替雷利珠单抗（TIS）+化疗（chemo）与单独化疗在晚期非鳞状非小细胞肺癌（nsq-NSCLC）一线治疗的临床结局研究

2022-04-12

howi (审核中...)

前往app查看评论内容

#肿瘤突变负荷#

ESMO Open：肿瘤突变负荷可预测口腔鳞状细胞癌患者预后

2021-06-17

howi (审核中...)

前往app查看评论内容

#肿瘤突变负荷#

Cancer Immunol Immunother：肿瘤突变评分(TMS)取代肿瘤突变负荷(TMB)预测NSCLC患者对ICI治疗的反应性？

2021-02-07

howi (审核中...)

前往app查看评论内容

#肿瘤突变负荷#

Clin Cancer Res：根据ctDNA量化的肿瘤突变负荷可很好的预测转移性NSCLC患者是否能从免疫治疗中获益

2021-02-06

howi (审核中...)

前往app查看评论内容

#肿瘤突变负荷#

Lancet Oncol：肿瘤突变负荷联合IFNγ基因表达特征可预测靶向治疗的III期黑色素瘤患者的预后

2020-02-05

howi (审核中...)

前往app查看评论内容

#肿瘤突变负荷#

[WCLC2017]胡洁教授深入解读ctDNA检测肿瘤突变负荷（TMB）在中国肺癌免疫治疗中的应用

2017-10-20

howi (审核中...)

前往app查看评论内容

#肿瘤突变负荷#

N Engl J Med：肿瘤突变负荷能为纳武单抗一线治疗晚期NSCLC争取一席之地吗

2017-06-30

科室
- - 订阅+
  - 更多科室
工具
服务